Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by cpacon Sep 20, 2019 10:57am
118 Views
Post# 30147750

RE:RE:RE:RE:RE:I'm interested in the science, but concerned about finances.

RE:RE:RE:RE:RE:I'm interested in the science, but concerned about finances.Actually, total debt is $160 million...  in addition to that, the company has a severe liquidity issue, current liabilities are more the 6 times what current assets are.  Finally, as I mentioned, the company has negative equity to the tune of $200 milllion...   As I said in my first post, the science is very interesting, but that could be overshadowed by the desperate state of the company's finances...  I'm neither long or short on RVX, just trying to assess what will be the bigger swing factor or whether this is in the 'too hard to determine' pile at this point.  Good luck.
Bullboard Posts